Racotumomab - A novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer

Drugs of Today

Volumn 50, Issue 4, 2014, Pages 301-307

  Gajdosik, Z ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

Cancer vaccine; NeuGcGM3; Non small cell lung cancer; Racotumomab

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM3; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; METHOTREXATE; PEMETREXED; RACOTUMOMAB; UNCLASSIFIED DRUG; VAXIRA; VINBLASTINE;

ABNORMAL LABORATORY RESULT; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNIZATION; CANCER INHIBITION; CHILL; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NONHUMAN; PARESTHESIA; PRURITUS; SKIN ALLERGY; UNCONSCIOUSNESS; VOMITING;

CANCER VACCINE; NEUGCGM3; NON-SMALL CELL LUNG CANCER; RACOTUMOMAB;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; G(M3) GANGLIOSIDE; HUMANS; LUNG NEOPLASMS; NEOPLASMS;

EID: 84899719886     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.4.2116670     Document Type: Article

References (24)

1. Ladjemi, M.Z. Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements. Front Oncol 2012, 2: 158.
2. Vazquez, A.M., Hernandez, A.M., Macias, A. et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol 2012, 2: 150.
3. Vazquez, A.M., Rodreguez-Zhurbenko, N., Lopez, A.M. Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front Oncol 2012, 2: 170.
4. Fernandez, L.E., Gabri, M.R., Guthmann, M.D. et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010, 2010: 814397.
5. rd Annu Meet Am Assoc Cancer Res (AACR) (March 31-April 4, Chicago) 2012, Abst LB-108.
6. Vazquez, A.M., Gabri, M.R., Hernandez, A.M., Alonso, D.F., Beausoleil, I., Gomez, D.E., Perez, R. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 2000, 7(4): 751-6.
7. Perez, A., Mier, E.S., Vispo, N.S., Vazquez, A.M., Perez Rodriguez, R. A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. Mol Immunol 2002, 39(1-2): 103-12. (Pubitemid 35245388)
8. Fuentes, D., Avellanet, J., Garcia, A. et al. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010, 120(2): 379-89.
9. Diaz, Y., Gonzalez, A., Lopez, A., Perez, R., Vazquez, A.M., Montero, E. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 2009, 58(7): 1117-28.
10. Segatori, V.I., Vazquez, A.M., Gomez, D.E., Gabri, M.R., Alonso, D.F. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol 2012, 2: 160.
11. Alfonso, M., Diaz, A., Hernandez, A.M. et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002, 168(5): 2523-9. (Pubitemid 34171859)
12. Neninger, E., Diaz, R.M., de la Torre, A. et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007, 6(2): 145-50. (Pubitemid 46641614)
13. Diaz, A., Alfonso, M., Alonso, R. et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003, 107(2): 80-9. (Pubitemid 36579371)
14. st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 2561.
15. th Eur Soc Med Oncol (ESMO) Congr (October 8-12, Milan) 2010, Abst 560.
16. Sampor, C., Guthmann, M.D., Scursoni, A. et al. Immune response to racotumomab in a child with relapsed neuroblastoma. Front Oncol 2012, 2: 195.
17. Alfonso, S., Diaz, R.M., de la Torre, A. et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 2007, 6(12): 1847-52. (Pubitemid 351590395)
18. st Eur Soc Med Oncol (ESMO) Istanbul) 2006, Abst 414P.
19. Hernandez, A.M., Toledo, D., Martinez, D. et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008, 181(9): 6625-34.
20. Macias, A., Alfonso, S., Santiesteban, E. et al. Active specific immunotherapy with racotumomab in the treatment of advanced non small cell lung cancer (NSCLC). Eur Soc Med Oncol (ESMO) Sci Edu Conf (September 28-October 2, Vienna) 2012, Abst 1238PD.
21. th World Conf Lung Cancer (July 3-7, Amsterdam) 2011, Abst 043.02.
22. th Eur Soc Med Oncol (ESMO) (October 8-12, Milan) 2010, Abst 559.
23. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 3086.
24. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst TPS3123.